The Fcc receptor IIIb (FccRIIIb), a receptor for the Fcc region of IgG, is specifically expressed on neutrophils. It has two allelic polymorphisms, NA1 and NA2, which are highly immunogenic and act as targets in alloimmune or autoimmune neutropenia. Thus, neutrophil antigens (NA) compatibility of donor/recipient pairs might be expected to affect the engraftment of neutrophils after allogeneic SCT (allo-SCT). Here, the impact of NA compatibility of 17 patients and their donors undergoing allo-SCT with a myeloablative regimen was determined. Leukocyte depletion filters were used for all transfusions before and post-SCT; most patients received G-CSF after transplant. Major mismatches for NA1 and NA2 were present in 1 and 7 patient/donor pairs, respectively. These eight patients receiving NA majormismatched allo-SCT were compared with nine patients who received NA compatible allo-SCT. Engraftment of neutrophils and the incidence of post-engraftment neutropenia were found to be identical in the two groups. Despite the limitations in statistical power because of the small number of patients analyzed, these observations suggest that the major mismatching for NA2 antigen has little impact on the engraftment of neutrophils after myeloablative allo-SCT, at least in patients transfused using leukocyte depletion filters and receiving G-CSF after transplantation.
Introduction
Allogeneic SCT (allo-SCT) using myeloablative-conditioning regimens results in profound neutropenia until graftderived hematopoiesis is established. Two types of pathological neutropenia can develop after allo-SCT 1 : failure to achieve a neutrophil engraftment, which is termed as primary neutropenia, and neutropenia following initial engraftment termed post-engraftment or secondary neutropenia. Differential diagnosis of pathological neutropenia following allo-SCT must take graft rejection, intrinsic SC failure, infection, GVHD, relapse of the underlying neoplasm and drug-induced myelosuppression into account. Moreover, Ab-mediated neutropenia has been increasingly recognized recently. 1 Ab-mediated neutropenia following allo-SCT can be caused either by autoimmune or alloimmune reactions. 1 Autoimmune neutropenia results from the interaction of donor-derived Abs with donorderived neutrophils or the interaction of recipient-derived Abs with recipient-derived neutrophils, whereas alloimmune neutropenia results from the interaction of recipientderived Abs with donor-derived neutrophils or vice versa. Several reports have suggested that the allo-SCT patients having 'major' mismatches for alloantigens on donor neutrophils are at high risk for alloimmune neutropenia, particularly if the mismatch involves a highly immunogenic neutrophil alloantigen system such as neutrophil antigens (NA) antigens. 2 The Fcg receptor IIIb (FcgRIIIb or CD16) is one of the three types of receptors for the Fcg region of IgG. 3 It is encoded by two distinct but highly homologous genes, FcgRIIIA and FcgRIIIB. 4 FcgRIIIa is a transmembrane receptor on natural killer cells and macrophages, whereas FcgRIIIb is a phosphatidylinositol-linked receptor on neutrophils. 4 The FcgRIIIB gene has two allelic polymorphisms of five nucleotides in the third exon, which generate two forms of neutrophil-specific antigen, NA1 and NA2. 5 It is known that feto-maternal incompatibility for NA antigens often results in alloimmune neonatal neutropenia. 6, 7 NA antigens are also the targets for auto-Ab both in patients with autoimmune neutropenia of infancy [8] [9] [10] and chronic idiopathic neutropenia in adults. 8, 11 Neutrophils homozygous for NA1 (NA1/NA1) or NA2 (NA2/NA2), NA1/NA2 heterozygous or with a biallelic deficiency (NAnull) 12, 13 are distinguishable from one another by specific monoclonal Abs.
14 Frequencies of the NA antigen isoforms differ between Caucasian and Japanese populations. NA1/NA1, NA1/NA2, NA2/NA2, and NA-null phenotypes are reported as 11.9, 45.1, 42.8 and 0.1% in the French, 7 but 31.3, 56.5, 12.2 and 0% in the Japanese.
14 Accordingly, in donor-recipient pairs of allo-SCTs, major mismatches in NA1 (NA1/NA1 or NA1/NA2 donor and NA2/NA2 recipient) could be more common in the Caucasians, whereas major mismatches in NA2 (NA1/NA2 or NA2/ NA2 donor and NA1/NA1 recipient) could be more common in the Japanese.
As most allo-SCT patients have received multiple blood transfusions before transplant, many may be presensitized against NA antigens expressed on the contaminating transfused neutrophils. Thus, preexisting alloimmunity against NA antigens might be detrimental to neutrophil engraftment and cause primary neutropenia after allo-SCT from NA antigen major-mismatched donors. In addition, the post-transplant generation of Ab against the donorderived NA antigen could be a possible cause of secondary neutropenia after engraftment in this setting. Despite this, the significance of major mismatches for NA antigen in primary and secondary neutropenia after allo-SCT is not known. Therefore, in this study, we have compared the engraftment of granulocytes and the incidence of postengraftment neutropenia between NA compatible and NA major-mismatched allo-SCTs performed in a single institute.
Materials and methods

Patients
Of the 21 consecutive myeloablative regimen allo-SCTs performed at the Department of Paediatrics, University of Yamanashi, from June 1999 to March 2004, three were excluded because of a lack of NA typing data, and, as a result, 18 Japanese patients were enrolled in the study. Informed consent for participation was obtained from the patients and/or their parents. In all transfusions of red blood cells and platelets both pretransplantation and post transplantation, post-storage leukodepletion was performed using leukocyte depletion filters to reduce contamination by donor neutrophils. After allo-SCT, G-CSF was administered routinely from day 4 until neutrophil engraftment (4500 Â 10 6 /l), except in patients with AML, myelodysplastic syndrome or ALL with myeloid antigen expression (although one patient who developed lifethreatening bacterial infection after transplantation was given G-CSF). Prophylaxis for pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole was discontinued immediately before conditioning for transplantation until stable neutrophil engraftment (at least 1000 Â 10 Typing for NA alleles Peripheral blood of 50-100 ml collected in EDTA was washed three times with ice-cold PBS containing 0.1% BSA and 0.1% NaN 3 (PBS) and incubated with TAG1 (anti-NA1), TAG2 (anti-NA2), TAG3 (anti-FcgRIII) monoclonal Abs, or normal mouse IgG 1 for 30 min on ice.
14 The erythrocytes were then lysed in buffer containing 8.26 g/l NH 4 Cl, 1.0 g/l KHCO 3 and 37 mg/l EDTA-4Na for 10 min on ice. Subsequently, the cells were washed three times with PBS and incubated with fluorescein isothiocyanate-conjugated anti-mouse polyvalent Ig for 30 min on ice. After washing with PBS, the cells were analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) by gating on neutrophils with a forward and side scatter profile. The NA typing of donor neutrophils was determined directly before transplantation in nine related donors and two unrelated donors, but indirectly after engraftment using patients' samples in seven unrelated donors.
Statistical analysis
All statistical analyses were performed with StatView (version 5.0.1) software. Student's t-testing and w 2 -testing were used to assess the significance of associations among different characteristics, and correlation ratio (Z 2 ) was used to assess the correlations between individual categories and engraftment of neutrophils.
Results
Patient characteristics and NA compatibility
Nine patients received allo-SCT from an NA incompatible donor; the remaining nine were compatible. One NA1/NA2 heterozygous patient received NA2 minor-mismatched allo-SCT from an NA1/NA1 homozygous donor, and was excluded from the analysis. Thus, eight patients who received NA major-mismatched allo-SCT (cases 1-8) were compared with nine patients who received an NA compatible transplant (cases 9-17) ( Table 1) . Seven NA1/ NA1 homozygous patients (cases 1-7) received NA2 majormismatched allo-SCT from NA1/NA2 heterozygous donors, whereas one NA2/NA2 homozygous patient (case 8) received NA1 major-mismatched allo-SCT from an NA1/ NA1 homozygous donor. Of the nine patients with NA compatible donors (cases 9-17), seven were NA1/NA2 heterozygous (cases 9-15) and the remainder were NA1/NA1 homozygous (cases 16 and 17).
Distributions of age, sex and underlying disease were similar between the two groups ( Table 1) . Before allo-SCT, all patients except case 13 in the NA compatible group were heavily transfused for pancytopenia owing to chemotherapy. Median numbers of units of RBC and platelet transfusions before allo-SCT were 20 and 210 U in the NA major-mismatched group, and 22 and 180 U in the NA compatible group, respectively (not significantly different). Transfusions after allo-SCT were also similar in the two groups. In the NA major-mismatched group, five patients received CBT from one HLA-matched and four HLA 1-2 loci-mismatched-unrelated donors, whereas three patients Neutrophil recovery after NA mismatched allo-SCT T Inukai et al received BMT from two HLA-matched and one HLA 2 loci-mismatched-related donor. In the NA compatible group, four patients received CBT from one HLAmatched-related and three HLA 1-3 loci-mismatchedunrelated donors, whereas five patients received BMT from four HLA-matched-related and one HLA-matched-unrelated donor. Sex-mismatched and ABO-incompatible transplantations were performed in six and five patients in the NA major-mismatch group, and in five and three patients in the NA compatible group, respectively. Distributions of conditioning regimens and GVHD prophylaxis were not different between the two groups. The number of transfused mononuclear cells did not differ between the two groups for BMT, but tended to be higher in the NA major-mismatched group (median, 4.8 Â 10 7 cells/kg) than in the NA compatible group (median, 2.4 Â 10 7 cells/kg) for CBT, although this difference was not statistically significant (P ¼ 0.067, unpaired t-test).
Neutrophil engraftment
Median times to engraftment of neutrophils (4500 Â 10 6 /l) were 21 days both in the NA major-mismatched and the NA compatible groups (Table 1 ). There were no significant differences between the groups (Figure 1) . The mean ± s.d. of times to engraftment of neutrophils was 23.3±10.2 days and 20.8 ± 8.8 days in the NA compatible group and the NA major-mismatched group, respectively, and the 95% confidence interval of the NA compatible group and NA major-mismatched group was calculated as À7.35 days and 12.52 days, respectively, suggesting limitations in statistical power because of the small size of samples. G-CSF was administered to five of eight patients in the NA majormismatched group and seven of nine patients in the NA compatible group (Table 1) . Neutrophil engraftment was significantly delayed in patients who did not receive G-CSF (n ¼ 5, median, day 33) as compared with those who did (n ¼ 12, median, day 17) (P ¼ 0.0004, unpaired t-test) (Figure 2 ). Among the patients who received G-CSF independently of NA compatibility, engraftment of neutrophils was significantly delayed following CBT (n ¼ 6, median, day 21) as compared with BMT (n ¼ 6, median, day 12) (P ¼ 0.0034, unpaired t-test) (Figure 2 ). Despite the limited number of patients, correlation ratio (Z 2 ) of administration of G-CSF in engraftment of neutrophils was 0.567 (P ¼ 0.00043) and that of sources of transplant (CBT versus BMT) among G-CSF administrated patients was 0.603 (P ¼ 0.0030) ( Table 2 ), demonstrating the statistically significant impact on engraftment of neutrophils. In contrast, the correlation ratio (Z 2 ) of the NA compatibility in engraftment of neutrophils was as low as 0.020 (Table 2 ). These observations suggested that the NA compatibility of donor/recipient pairs was less critical in engraftment of neutrophils than were administration of G-CSF and sources of transplant. Acute GVHD was observed in seven of eight patients in the NA major-mismatched group and seven of nine in the NA compatible group. Grade 3 GVHD occurred in three patients who underwent unrelated CBT from HLA-mismatched donors in the NA major-mismatched group, but did not develop in the NA compatible group. This difference was statistically significant (P ¼ 0.043, w 2 -test). Median time to engraftment of erythrocytes (reticulocytes 41.0%) and platelets (420 Â 10 9 /l) was 22 and 32 days in the NA majormismatched group and 28 and 31 days in the NA compatible group, respectively (Table 1 ). These differences were not statistically significant (Figure 1) . Engraftment of erythrocytes and platelets was significantly delayed after CBT as compared with after BMT (P ¼ 0.0034 for erythrocyte engraftment and P ¼ 0.0010 for platelet engraftment, unpaired t-tests) (Figure 2 ). Three patients in the NA major-mismatched group (cases 4, 5 and 8) and two patients in the NA compatible group (cases 10 and 13), who did not receive G-CSF, required a longer time to engraftment of neutrophils than erythrocytes (Table 1) .
Post-engraftment neutropenia
Post-engraftment neutropenia is defined as a decrease in the neutrophil count to below 500 Â 10 6 /l for a minimum of 2 consecutive days following initial engraftment with a neutrophil count of at least 1000 Â 10 6 /l for a minimum of 2 consecutive days. 15 In the NA major-mismatched group, Table 1 ). It can be noted that all three patients developed neutropenia immediately after the cessation of G-CSF administration and recovered spontaneously within 1 week. Absolute numbers of neutrophils before and 1, 2, 3 and 6 months after allo-SCT were compared between the two groups (Figure 3) , and there were no significant differences.
Discussion
There have been increasing numbers of reports of immune neutropenia following allo-SCT. 1 Klumpp et al. 2 reported a case of graft failure with profound neutropenia following NA1-mismatched allo-SCT. In that case, the donor's and the patient's neutrophil phenotypes were NA1/NA2 and NA2/NA2, respectively, and the patient's serum at the onset of neutropenia showed reactivity against homozygous NA1-positive but not NA1-negative neutrophils. Warkentin et al. 16 reported successful engraftment of NA1-positive BM from a sibling donor by pretransplant plasma exchange in an aplastic anemia patient with a high titer of anti-NA1 Ab because of frequent transfusions. In a prospective analysis of allo-SCT patients, Tazzari et al. (open symbols) administration of G-CSF in NA major-mismatched and compatible groups. The P-value was calculated by unpaired t-testing. CBT, cord blood transplants.
Table 2
Correlation ratio of NA comatibility in netrophil engraftment that these patients showed a tendency toward having lower levels of peripheral neutrophils up to 6 months after allo-SCT. Of the 14 patients whose sera were positive for neutrophil Abs by the indirect test, one had specific anti-NA1 reactivity. In addition, two patients' samples eluted from neutrophils showed anti-NA1 reactivity. Klumpp et al. 15 reported another prospective analysis suggesting a negative association between the presence of Abs reactive with neutrophils and time to neutrophil engraftment. Although antigen specificity could not be determined because of the small amount of serum available, of 22 patients who underwent allogeneic BMT and 14 who underwent autologous BMT, 16 (44%) had Abs reactive with neutrophils after SCT and suffered a significantly greater incidence of post-engraftment neutropenia.
In this study, NA compatibility between the patients and their donors for allo-SCT was analyzed. Consistent with our previous report that the frequencies of NA1/NA1, NA1/NA2 and NA2/NA2 in healthy Japanese blood donors are 31.3, 56.5 and 12.2%, respectively, 14 NA incompatibility was observed in half of the patient-donor pairs analyzed. Among the NA incompatible allo-SCTs, major mismatch for the NA2 antigen was common. Thus, seven patients were NA2 major-mismatched, but only one was NA1 major-mismatched. Times to engraftment of neutrophils and the incidence of post-engraftment neutropenia did not differ between NA major-mismatched and NA compatible groups. In contrast, despite the limited number of patients, administration of G-CSF and sources of transplant (CBT versus BMT) among G-CSF treated patients showed statistically significant impact on engraftment of neutrophils. Thus, NA compatibility of donor/ recipient pairs seems to have less impact on engraftment of neutrophils when compared with administration of G-CSF and sources of transplant.
In autoimmune neutropenia in infancy, the anti-NA1 Ab is reported to be 8-10 times more common than anti-NA2 Ab in Caucasians, 9, 10 in whom NA2 homozygotes are much more common than NA1 homozygotes, 7 suggesting that NA1 could be highly immunogenic. In contrast, NA1 homozygotes are more common than NA2 homozygotes in Japan, and a higher incidence of mismatch for the less immunogenic NA2 antigen could be one of the reasons for the minimal impact of NA incompatibility on the engraftment of neutrophils after allo-SCT in Japanese patients.
Administration of G-CSF after allo-SCT has been reported to decrease the time required for neutrophil recovery. 18, 19 Moreover, although there have been reports of unsuccessful cases, 20, 21 G-CSF has been found to be effective for neutrophil recovery in patients with alloimmune neonatal neutropenia 22 as well as autoimmune neutropenia after allo-SCT. 23 In this study, G-CSF was administered to five of eight patients who underwent NA major-mismatched allo-SCT. Accordingly, there is a possibility that the use of G-CSF might have masked a possible delay of neutrophil recovery after NA majormismatched allo-SCT.
As most allo-SCT patients are polytransfused before transplant, alloimmune responses against NA antigens might be provoked by neutrophil-specific antigens derived from contaminating neutrophils that are absent from the patient's neutrophils. In our department, post-storage leukocyte removal is performed routinely using leukocyte depletion filters to prevent HLA-alloimmunization and/or platelet refractoriness caused by transfusion. 24 As a result, the elimination of contaminating neutrophils could have reduced the risk of alloimmunization against the NA antigen. However, we cannot formally prove this because we did not test for Abs reacting with neutrophils in this study. Thus, further studies regarding association of the NA typing of patients with alloimmunization against the NA antigen are required. Nonetheless, it is likely that the routine use of leukodepletion might have contributed to the minimal impact of NA major mismatch on the engraftment of neutrophils after allo-SCT reported here.
In this study, the myeloablative regimen resulted in substantial destruction of host immune function before transplantation. Recently, reduced intensity nonmyeloablative regimens, in which host immune function is not immediately abrogated before and after allo-SCT, is becoming widely used to reduce regimen-related toxicity in patients at advanced age or with less stable medical conditions. In ABO-incompatible allo-SCT, it has been reported that erythrocyte engraftment was markedly delayed following employment of nonmyeloablative as compared with myeloablative regimens. 25 Thus, it might be predicted that NA incompatible transplantation might have a greater impact on engraftment of neutrophils following allo-SCT performed with nonmyeloablative regimens. Careful observation of neutrophil engraftment after nonmyeloablative allo-SCT from an NA incompatible donor is therefore warranted. Taken together, although a relatively small number of patients were analyzed in this study, it strongly suggested that major mismatches for the NA2 antigen have little impact on the engraftment of neutrophils after allo-SCT, at least following myeloablative regimens and in patients transfused using leukocyte depletion filters and given G-CSF post transplant. Further analysis is required to establish the significance of mismatching for the NA1 antigen and the impact of NA compatibility on allo-SCT following a nonmyeloablative conditioning regimen.
